Rat Cripto / TDGF1 Protein (Fc Tag)
FGFR-4
- 100ug (NPP3130) Please inquiry
| Catalog Number | P80135-R02H |
|---|---|
| Organism Species | Rat |
| Host | Human Cells |
| Synonyms | FGFR-4 |
| Molecular Weight | The recombinant rat TDGF1/Fc is a disulfide-linked homodimer. The reduced monomer comprises 368 amino acids and predicts a molecular mass of 41 kDa. The apparent molecular mass of the rat TDGF1/Fc monomer is approximately 45 kDa in SDS-PAGE under reducing conditions. |
| predicted N | Phe 17 |
| SDS-PAGE |  |
| Purity | > 90 % as determined by SDS-PAGE |
| Protein Construction | A DNA sequence encoding the rat TDGF1 (XP_001056317.2) (Met 1-Cys 143) was fused with the Fc region of human IgG1 at the C-terminus. |
| Bio-activity | |
| Research Area | Immunology |Signal Transduction |Growth Factor & Receptor |Wnt Ligands & Receptors |Wnt Receptors |
| Formulation | Lyophilized from sterile PBS, pH 7.4 1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. |
| Background | Cripto/TDGF1 is a member of the epidermal growth factor (EGF)- Cripto, Frl-1, and Cryptic (CFC) family. EGF-CFC family member proteins share a variant EGF-like motif, a conserved cysteine-rich domain, and a C-terminal hydrophobic region. Before gastrulation, Cripto is asymmetrically expressed in a proximal–distal gradient in the epiblast, and subsequently is expressed in the primitive streak and newly formed embryonic mesoderm. These proteins play key roles in intercellular signaling pathways during vertebrate embryogenesis. Mutations in Cripto/TDGF1 can cause autosomal visceral heterotaxy. Cripto/TDGF1 is involved in left-right asymmetric morphogenesis during organ development. Cripto signalling is essential for the conversion of a proximal–distal asymmetry into an orthogonal anterior–posterior axis. The mechanism of inhibitory effects of the Cripto includes both cancer cell apoptosis, activation of c-Jun-NH(2)-terminal kinase and p38 kinase signaling pathways and blocking of Akt phosphorylation. Thus, Cripto is a unique target, and Immunohistochemistry to Cripto could be of therapeutic value for human cancers. |
| Reference |